TMP-SMX


Also found in: Acronyms.

TMP-SMX

Trimethoprim-sulfamethoxazole, Bactrim, Septra AIDS A drug combination used for PCP pneumonia, toxoplasmosis as well Adverse effects Allergies, fever, itchy rash, N&V, neutropenia. See AIDS.

Trimethoprim-sulfamethoxazole (TMP-SMX)

An antibiotic used to treat and prevent PCP.

TMP-SMX,

n acronym for trimethoprim-sulfamethoxazole.
References in periodicals archive ?
falla del tratamiento y resistencia bacteriana al TMP-SMX en Escherichia coli aislada en frotis rectales.
Despite the Botswana Ministry of Health's recommendation to administer co-trimoxazole as the drug of choice for cutaneous bacterial infections, which is supported by current US guidelines advocating TMP-SMX as the first-line therapy against community-acquired MRSA, S.
01 TMP-SMX ([paragraph]) 0 0 NA Vancomycin 0 0 NA * p value compares resistance to indicated antimicrobial drugs or positive test result among adult vs.
TMP-SMX and amoxicillin had the highest resistance rates of 54% (N=15) and 46% (N=13) respectively, followed by cefuroxime 14% (N=4) and ciprofloxacin and nitrofurantoin with 11% (N=3) resistance (Fig.
In Latin America, MRSA clones are genetically diverse, but often share in common genes that encode for multidrug resistance to--lactams, erythromycin, chloramphenicol and clindamycin, and variable resistance to rifampin, fluorquinolones and TMP-SMX.
05, chi-square test) to ampicillin and TMP-SMX than ETEC and EAEC.
TMP-SMX is the drug of choice in the treatment of uncomplicated community-acquired UTIs in areas where the resistance rate is less than 10%.
8 Duration from Antibiotics at WISN onset to Case WISN onset Site of WISN wound infection 1 ART, HRZES, Breasts, L thigh 21 days TMP-SMX, ceftriaxone 2 ART, HRZE R buttock 26 days 3 ART, HRZE, Buttocks 17 days ampicillin, amikacin 4 HRZE L breast 37 days 5 HRZE L breast, L hip 6 HRZE, L thigh metronidazole, TMP-SMX Wound culture Case from WISN site Antimicrobial sensitivities 1 S.
But neither fluoroquinolones nor TMP-SMX have a clear effect on toxin production, and bacterial resistance frequently emerges during therapy with clindamycin.
The patient was given high-dose intravenous TMP-SMX and had a favorable clinical response.
But as the use of TMP-SMX for UTIs has decreased, resistance to other antimicrobial agents has been increasing.